ArticlePediatric research2026
Serum intestinal fatty acid binding protein is elevated during feeding advancement in necrotizing enterocolitis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Evidence, Controversies, and the Future of Biotics in the Prevention of Necrotizing Enterocolitis: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- A digestive cartridge reduces intestinal injury in a murine model of necrotizing enterocolitis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn retrospective studies, intestinal fatty acid binding protein (I-FABP) has been suggested as a potential biomarker to identify NEC prior to clinical diagnosis. We hypothesize that increasing I-FABP levels with feeding advancement may be a biomarker of intestinal stress prior to clinical suspicion of NEC.
methodsProspective study of neonates ≤ 32-week gestation and ≤1500 grams enrolled within 72 h of life. Blood was obtained for biomarker assessment with feeding advancement. ELISA was used to assay serum I-FABP (sI-FABP).
resultsOf 96 patients enrolled, 9 were diagnosed with NEC. sI-FABP values remained low in healthy controls and NEC patients at the initial stages of feeding, up to 60 mL/kg/day. In those who developed NEC, there was a significantly higher sI-FABP at the final sample compared to their own earlier samples (p < 0.0001) or matched controls (p < 0.001). Those who developed NEC while feed volumes were being increased had a significantly higher sI-FABP than others. Receiver operating characteristic (ROC) curve analysis identified sI-FABP of 4.8 ng/mL to be predictive of early NEC with 80% sensitivity and 100% specificity (AUC 0.92; p < 0.01).
conclusionElevation in sI-FABP with increasing volume of enteral feeds correlates with, and precedes, clinical suspicion of NEC. IMPACT: Serum intestinal fatty acid binding protein elevation during feeding advancement is a sensitive and specific biomarker for necrotizing enterocolitis that precedes clinical suspicion. Early and accurate identification of infants at risk for necrotizing enterocolitis prior to development of symptoms allows the identification of patients at risk that may benefit from early intervention or trial of potential therapies.
Indexed as
Identifiers
41318798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.